2019 was a spectacular year for Amarin (NASDAQ:AMRN). The same has not been true of 2020, at least looking at Amarin stock.Source: Pavel Kapysh / Shutterstock.com After a 7% decline on Wednesday, AMRN now has dropped 24% so far this year. Truthfully, it's difficult to see why.There really hasn't been any bad news to explain the decline. In fact, there hasn't been much in the way of news at all.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBroad markets have plunged in recent sessions, but Amarin stock shouldn't have that much exposure to those movements. Pharmaceutical stocks on the whole admittedly have been weak. Yet AMRN's year-to-date decline is almost five times that of the iShares U.S. Pharmaceuticals ETF (NYSE:IHE), which has fallen less than 5%. * 10 Stocks to Buy for Your 10-Year-Old Simply put, trading in AMRN has been odd. And it has offset the valuation concerns I've...
(Bloomberg) -- Beyond Meat Inc. shares fell the most in four months despite posting revenue that blew past analysts’ estimates -- a sign investors may be looking for more than rapid sales growth from the faux meat maker.The company’s fourth-quarter sales of $98.5 million exceeded the highest analyst projection and helped push full-year revenue beyond expectations to $297.9 million. Beyond Meat, which reported after the close on Thursday, forecast 2020 sales of $490 million to $510 million, also topping estimates.Chief Executive Officer Ethan Brown said the company is “only scratching the surface” of the U.S. restaurant market, but investors may be impatient for a bigger deal with a major player like McDonald’s Corp. Beyond Meat is in about 4% of the 650,000 restaurants in the U.S., Brown said, referring to the low number as an opportunity for rapid growth.The company’s forecast that adjusted Ebitda -- earnings excluding items such as interest...